Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2024 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 5.610-6.045 for the period. The company issued revenue guidance of $51.7 billion-$53.9 billion.

Analyst Ratings Changes

Separately, Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold”.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY traded up $0.05 during mid-day trading on Friday, hitting $5.41. 1,870,487 shares of the company’s stock were exchanged, compared to its average volume of 1,451,287. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The stock’s 50-day moving average is $7.34 and its 200-day moving average is $7.41. Bayer Aktiengesellschaft has a fifty-two week low of $5.33 and a fifty-two week high of $11.33.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. The company had revenue of $10.96 billion during the quarter. On average, analysts forecast that Bayer Aktiengesellschaft will post 1.33 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.